Senate Files

Bills

S. 2276 119th Congress

ETHIC Act

Latest action, Jul 15, 2025: Read twice and referred to the Committee on the Judiciary.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

2 cosponsors

Sponsored by Peter Welch (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
1 D · 1 R
  • Democrat
  • Republican
  • Independent
2 senators cosponsoring

Referred to: Senate: Judiciary Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

23 clientsQ2 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)
6 reports
COUNCIL FOR INNOVATION PROMOTION (C4IP)
RADIUS ADVOCACY, LLC
6 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
6 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
5 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
5 reports
COUNCIL FOR INNOVATION PROMOTION (C4IP)
5 reports
FRESENIUS KABI
S-3 GROUP
5 reports
FRESENIUS KABI USA LLC
5 reports
GSK (FKA GLAXOSMITHKLINE INC.)
5 reports
JOHNSON & JOHNSON SERVICES INC
5 reports
NOVARTIS
5 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
5 reports
AMGEN INC
4 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
4 reports
PUBLIC CITIZEN
4 reports
All 25 of 29 clients
ClientLobbying firmReportsReports totalingFromToSenate
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)6$60KQ4 2025Q3 2026yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)RADIUS ADVOCACY, LLC6$0Q4 2025Q3 2026yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.6$540KQ4 2025Q3 2026yes
ASSOCIATION FOR ACCESSIBLE MEDICINES5$4.3MQ4 2025Q3 2026yes
BIOTECHNOLOGY INNOVATION ORGANIZATION5$9.4MQ4 2025Q3 2026yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)5$450KQ4 2025Q3 2026yes
FRESENIUS KABIS-3 GROUP5$0Q4 2025Q3 2026yes
FRESENIUS KABI USA LLC5$3.1MQ4 2025Q3 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)5$6.6MQ4 2025Q3 2026yes
JOHNSON & JOHNSON SERVICES INC5$11.2MQ4 2025Q3 2026yes
NOVARTIS5$8.9MQ4 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA5$44.0MQ4 2025Q3 2026yes
AMGEN INC4$11.7MQ4 2025Q3 2026yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC4$200KQ4 2025Q2 2026yes
PUBLIC CITIZEN4$406KQ4 2025Q3 2026yes
SANOFI US SERVICES INC4$5.8MQ4 2025Q3 2026yes
CONSERVATIVES FOR PROPERTY RIGHTSELITE STRATEGIC SERVICES3$148KQ4 2025Q1 2026yes
FAMILIES USA FOUNDATION INC3$45KQ1 2026Q3 2026yes
T1INTERNATIONAL USA3$0Q1 2026Q3 2026yes
BAYER CORPORATION (CONSOLIDATED REPORT)2$3.5MQ2 2026Q3 2026yes
CENTER FOR INDIVIDUAL FREEDOM2$20KQ4 2025Q3 2025yes
CHAMBER OF COMMERCE OF THE U.S.A.2$33.4MQ2 2026Q3 2026yes
NFIB (NATIONAL FEDERATION OF INDEPENDENT BUSINESS)2$3.6MQ2 2026Q3 2026yes
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2$6.2MQ3 2025Q3 2026yes
APOTEX CORP.1$730KQ1 2026Q1 2026yes